Jubilant Ingrevia: Business Overview & Financial Analysis
Jubilant Ingrevia is an integrated global life science products and solutions enterprise headquartered in Noida, Uttar Pradesh. Promoted by the Shyam S. Bhartia and Hari S. Bhartia led Jubilant Bhartia Group, the company operates across chemical synthesis, nutrition, and specialty ingredients. Managing integrated manufacturing complexes in Uttar Pradesh, Gujarat, and Maharashtra, Jubilant Ingrevia supplies pyridine and picolines, diketene derivatives, bio-based acetyls, vitamin B3 (niacinamide), and custom synthesis (CDMO) solutions to global pharmaceutical, agrochemical, nutrition, and consumer care majors across domestic and international markets.
Business Segment Revenue Breakdown of Jubilant Ingrevia (Q1 FY27)
Jubilant Ingrevia structures its operational manufacturing turnover across specialty chemicals, nutrition and health solutions, and chemical intermediates.
- Specialty Chemicals Division – 48.5% of Total Operating Revenue
- Chemical Intermediates Division – 32.2% of Total Operating Revenue
- Nutrition & Health Solutions Division – 19.3% of Total Operating Revenue
- Total Consolidated Revenue from Operations (Q1 FY27) – Rs 1,185.40 crore (+12.5% YoY)
Specialty chemicals serve as the primary revenue and margin engine, offering custom synthesis, pyridine derivatives, and diketene chemistry. Chemical intermediates supply bio-based acetyls to domestic industrial accounts, while nutrition solutions deliver vitamin B3 and animal nutrition supplements.
Geographic Revenue Mix & Export Footprint of Jubilant Ingrevia (FY26)
Jubilant Ingrevia balances direct domestic ingredient sales in India with direct exports to international life science manufacturers.
- Domestic Indian Market Sales Share – 52.0% of Total Operating Revenue
- International Exports Channel Share – 48.0% of Total Operating Revenue
- Key Export Destinations Share – Europe (~38% of exports), North America (~32%), Asia-Pacific & Japan (~30%)
- Global Destination Footprint – Exports to 50+ countries across regulated and emerging markets
International exports generate nearly half of operational turnover, supported by direct global supply contracts. Domestic sales supply integrated Indian pharmaceutical formulation exporters, agrochemical formulators, and consumer care brands.
Product Portfolio & Global Market Leadership of Jubilant Ingrevia (FY26)
Jubilant Ingrevia maintains global market leadership positions across pyridine chemistry, diketene derivatives, and vitamin B3 manufacturing.
- Global Market Position in Pyridine & Picolines – World's lowest-cost producer and Top 2 global leader
- Global Market Position in Vitamin B3 (Niacinamide) – Top 2 global manufacturer
- Diketene Chemistry Derivative SKUs – 20+ commercial diketene-based specialized molecules
- Total Commercial Product Portfolio – 130+ specialized chemical SKUs and ingredient formulations
The company operates a vertically integrated value chain starting from bio-ethanol based acetyls up to advanced pyridine and diketene derivatives. Global leadership in pyridine and vitamin B3 provides baseline volume scale and raw material cost advantages.
Manufacturing Infrastructure & Facilities Scale of Jubilant Ingrevia (FY26)
Jubilant Ingrevia operates multi-location chemical synthesis complexes equipped with continuous processing reactors, distillation towers, and effluent treatment units.
- Primary Manufacturing Locations – Gajraula (Uttar Pradesh), Bharuch (Gujarat), and Nira (Maharashtra)
- Total Combined Manufacturing Land Area – 1,100+ acres across integrated industrial sites
- World-Scale Pyridine Capacity – Single-location largest pyridine manufacturing complex at Gajraula
- Captive Power & Utility Capacity – 85+ MW captive co-generation power generation facilities
- Global Compliance Certifications – ISO 9001, ISO 14001, FSSC 22000, and cGMP accredited suites
Manufacturing complexes in Gajraula and Bharuch house multi-purpose synthesis plants and continuous flow chemistry reactors. Holding captive co-generation power plants and zero-liquid-discharge (ZLD) units ensures cost-competitive utility supply and environmental compliance.
Latest Quarterly Financial Performance of Jubilant Ingrevia (Q1 FY27)
Jubilant Ingrevia recorded top-line revenue expansion and operating margin recovery during the first quarter of FY27.
- Consolidated Revenue from Operations – Rs 1,185.40 crore (+12.5% YoY)
- Consolidated Operating EBITDA – Rs 168.50 crore (+18.2% YoY)
- Operating EBITDA Margin – 14.21% (+68 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 92.40 crore (+22.5% YoY)
- CDMO & Specialty Chemicals Share in Quarterly Revenue – 52.0%
First-quarter operating revenue rose 12.5% year-on-year to Rs 1,185.40 crore, supported by volume recovery in specialty chemicals and CDMO project executions. Consolidated Net Profit After Tax reached Rs 92.40 crore, while operating EBITDA margins expanded to 14.21%.
Consolidated Annual Financial Performance of Jubilant Ingrevia (FY26)
Jubilant Ingrevia delivered full-year turnover expansion and operating profit growth for full financial year FY26.
- Full Year Consolidated Revenue from Operations – Rs 4,450.40 crore (+10.8% YoY)
- Full Year Operating EBITDA – Rs 585.20 crore (+14.5% YoY)
- Full Year Operating EBITDA Margin – 13.15% (+42 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 312.50 crore (+18.2% YoY)
- Return on Capital Employed (ROCE) – 16.8%
Full-year operating turnover crossed Rs 4,450 crore in FY26, as consolidated Net Profit After Tax expanded 18.2% to Rs 312.50 crore. Operational performance was supported by diketene plant capacity utilization, specialty volume expansion, and input cost stabilization.
Capital Structure & Financial Health Ratios of Jubilant Ingrevia (Q1 FY27)
Jubilant Ingrevia maintains a disciplined capital structure supported by operational cash flow conversion and low financial debt gearing.
- Debt to Equity Ratio – Low Debt (0.22x)
- Total Cash, Bank Balances & Liquid Investments – Rs 350.00 crore
- Total Consolidated Net Worth Base – Rs 2,850.00 crore
- Return on Equity (ROE) – 11.5%
- Working Capital Cycle – 58 days
Total net worth expanded to Rs 2,850.00 crore as of June 30, 2026, with debt to equity holding low at 0.22x. Operational cash flow generation fully supports ongoing capital expenditure programs without stretching leverage metrics.
Capital Expenditure & Expansion Pipeline of Jubilant Ingrevia (FY27–FY28)
Jubilant Ingrevia executes multi-year capital allocation outlays to scale diketene derivatives, agrochemical active ingredients, and CDMO infrastructure.
- Total Planned Multi-Year Capex Outlay – Rs 600–800 crore over FY27–FY28
- Bharuch Diketene Expansion Outlay – Setting up downstream diketene derivative synthesis blocks
- Agrochemical Intermediates & Actives Outlay – Constructing dedicated multi-purpose plants (MPPs) for global agro majors
- CDMO GMP Facility Upgrade – Scaling cGMP pilot plants and R&D suites at Gajraula
- Funding Method – 80% funded through internal operational cash accruals and 20% debt facilities
Capital expenditure is budgeted at Rs 600–800 crore over FY27–FY28 to expand diketene derivative blocks and construct dedicated agrochemical synthesis units. Internal cash flow conversion funds eight-tenths of planned expansions to preserve balance sheet strength.
Management Commentary & Strategic Outlook of Jubilant Ingrevia (Q1 FY27 Concall)
Management guidance outlines strategic priorities centered on specialty chemical volume scaling, CDMO business expansion, and margin protection.
- Management targets achieving a 12%–15% annual revenue CAGR over the FY27–FY29 period.
- Operating EBITDA margins are guided to expand toward the 15.0%–16.5% corridor through product mix enrichment.
- Specialty Chemicals and CDMO share in overall revenue is targeted to reach 55% over the next 2 to 3 years.
- Diketene derivative capacity commercialization will focus on supplying high-margin pharmaceutical and agrochemical clients.
- Capital allocation strategy will maintain debt to equity below 0.40x while funding greenfield and brownfield capex.
Management anticipates global customer supply-chain diversification and domestic pharmaceutical demand to support volume growth. Operational focus centers on commissioning new multi-purpose plants in Bharuch, scaling CDMO contracts, and maintaining balance sheet discipline.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Jubilant Ingrevia Q1 FY27 Consolidated Financial Disclosures & Press Release (July/August 2026)
- Jubilant Ingrevia Q1 FY27 Investor Presentation (July/August 2026)
- Jubilant Ingrevia Q4 & Full Year FY26 Consolidated Financial Disclosures (May 2026)
- BSE Limited & National Stock Exchange of India (NSE) Corporate Filings for Jubilant Ingrevia
- Ticker Finology Jubilant Ingrevia Page
Disclaimer
The information presented above on Jubilant Ingrevia has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Jubilant Ingrevia page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.